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Fabry disease: Detection of undiagnosed hemodialysis patients
and identification of a “renal variant” phenotype.
Background. Fabry disease is an X-linked recessive lyso-
somal storage disease resulting from deficient -galactosidase
A (-Gal A) activity. Renal failure is a major debilitating
complication in classically affected males. To determine if this
disorder is underdiagnosed in patients with end-stage renal
disease (ESRD), the frequency of unrecognized males with
Fabry disease on chronic hemodialysis was determined.
Methods. Plasma -Gal A activity was measured in 514 con-
secutive males with ESRD on hemodialysis. Patients with low
-Gal A activity were evaluated clinically and their -Gal A
mutations were determined.
Results. Six (1.2%) of 514 hemodialysis patients had low
plasma -Gal A activities and a previously identified (E66Q,
A97V, M296I) or novel (G373D) missense mutation. At ages
30 to 68 years, five patients lacked the classic manifestations
of angiokeratoma, acroparesthesias, hypohidrosis, and ocular
opacities, while the sixth lacked angiokeratoma and ocular
changes. Five had left ventricular hypertrophy (LVH).
Conclusion. The clinical spectrum of Fabry disease includes
a “renal variant” phenotype in patients without classic symp-
toms who develop ESRD. Affected males undergoing hemodi-
alysis or renal transplantation can be readily diagnosed by
plasma -Gal A assays. These patients and their family mem-
bers may benefit from enzyme replacement therapy for the
later, life-threatening cardiovascular and cerebrovascular com-
plications of Fabry disease.
Fabry disease is an X-linked recessive lysosomal stor-
age disorder resulting from the deficient activity of the
lysosomal hydrolase, -galactosidase A (-Gal A) [1–3].
1See Editorial by Gru¨nfeld, p. 1136.
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The enzymatic defect leads to the progressive accumula-
tion of glycosphingolipids, predominantly globotriaosyl-
ceramide (GL-3), throughout the body, and particularly
in blood vessels, kidney, and heart [3–6]. Affected males
who have little, if any, -Gal A activity exhibit the “classi-
cal” Fabry phenotype with onset of acroparesthesias,
angiokeratoma, hypohidrosis, and corneal and lenticular
opacities in childhood or adolescence. With advancing age,
the progressive lysosomal GL-3 accumulation, particularly
in the vascular endothelium, leads to renal failure, vascu-
lar disease of the heart and brain, and premature demise.
In contrast, female carriers for the classic phenotype
have a range of clinical involvement due to random
X-inactivation [7], ranging from most being asymptom-
atic or having mild manifestations to rare carriers having
as severe disease as affected males [3].
Recently, a variant form of Fabry disease was identi-
fied with manifestations primarily limited to the heart
[8–11]. These “cardiac variants” lack the classical disease
symptoms, and present in the sixth or seventh decade
of life with left ventricular hypertrophy (LVH) and/or
cardiomyopathy. They may have proteinuria, but their
renal function is typically normal for age. Of note, “car-
diac variants” have residual -Gal A activity due to mis-
sense mutations and lack the systemic vascular endothelial
glycosphingolipid deposition characteristic of classically
affected patients [3]. Screening of 230 consecutive Japa-
nese male patients with LVH and 153 British male pa-
tients with hypertrophic cardiomyopathy by plasma
-Gal A assays revealed that 3% and 3.9%, respectively,
were previously unrecognized “cardiac variants” [11, 12].
Early diagnosis of Fabry disease is important because
it permits family studies to identify other affected rela-
tives for genetic counseling and therapeutic intervention.
This is especially true now that clinical studies have
shown the safety and effectiveness of enzyme replace-
ment therapy for Fabry disease [13–16], as well as the
potential for enzyme enhancement therapy [17, 18]. En-
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zyme replacement therapy is currently available in many
countries and is pending approval in others. However,
because Fabry disease is not common or well known and
its early classical manifestations tend to be nonspecific,
the disorder often is unrecognized, misdiagnosed, or di-
agnosed late in life [3, 19].
To determine if Fabry disease is underdiagnosed among
male patients with end-stage renal disease (ESRD), ef-
forts were undertaken to screen patients in chronic he-
modialysis clinics in the Japanese prefectures of Kago-
shima and Miyazaki. In this communication, we report
that six (1.2%) of 514 consecutive male hemodialysis
patients had deficient-Gal A activity and Fabry disease.
Notably, five of the six patients did not have the classical
disease manifestations, including acroparesthesias, angi-
okeratomas, hypohidrosis, or corneal and lenticular le-
sions. These patients extend the clinical spectrum of
Fabry disease and identify a “renal variant” phenotype.
METHODS
Patients
A total of 514 consecutive, unselected Japanese male
patients with ESRD treated with chronic hemodialysis
at clinics in the Kagoshima and Miyazaki Prefectures
were screened with informed consent for Fabry disease
by measuring their plasma -Gal A activities. The pa-
tients ranged in age from 20 to 90 years (mean  1 SD,
54  17 years).
Clinical evaluation
The six patients with abnormally low plasma and lym-
phocyte -Gal A activities were evaluated for the clinical
manifestations of classical Fabry disease, including angi-
okeratoma, acroparesthesias, hypohidrosis, corneal and
lenticular opacities, and cardiomegaly by clinical history,
physical examination, slit-lamp microscopy, and echocar-
diography. The criterion for LVH was a ventricular sep-
tum and/or posterior wall thickness of at least 13 mm
[20]. In addition, the family members of patients 5 and
6 were examined clinically, and urinary protein, serum
creatinine, and plasma -Gal A activity were deter-
mined. Of note, only 16 (3.1%) of the 514 patients had
renal biopsies before chronic hemodialysis, including pa-
tient 6, who had a biopsy 15 years prior to this study for
evaluation of his proteinuria. This biopsy was routinely
fixed, stained with periodic-acid Schiff (PAS), and exam-
ined by light microscopy. For this study, the original
PAS-stained slides were reexamined, and the original
biopsy specimen was osmium-fixed, embedded in epoxy-
resin, cut, and stained with toluidine blue O for light
microscopy. In addition, ultrathin sections, cut and dou-
bly stained with uranyl acetate and lead citrate, were
examined by transmission electron microscopy.
Measurement of -Gal A activity and GL-3 levels
Plasma -Gal A activity was measured before hemodi-
alysis in all 514 patients with renal failure and was as-
sessed in 89 healthy Japanese male subjects ranging from
14 to 80 years of age (mean  1 SD, 52  19 years)
who served as controls. Plasma or lymphocyte -Gal A
activity was determined with the fluorogenic substrate,
4-methylumbelliferyl--D-galactopyranoside (Sigma
Chemical Co., St. Louis, MO, USA) as previously de-
scribed [3], except that the reaction mixture included 500
mol/L of -N-acetyl-d-galactosamine (Nacalai Tesque,
Kyoto, Japan) to inhibit the -N-acetylgalactosamini-
dase activity [21]. Plasma -Gal A activities of 2.5
U/mL were defined as abnormally low. Lymphocyte
-Gal A activity was determined in the six patients who
had low plasma -Gal A activity, as well as in 43 healthy
Japanese male subjects ranging in age from 24 to 46
years. A unit (U) of enzymatic activity is that amount
of enzyme required to hydrolyze 1 nmol of substrate
per hour at 37C. Plasma GL-3 levels in ng/mL were
determined as previously described [22].
Mutation analysis
Genomic DNA was isolated from whole blood with
the DNA Extractor WB Kit (Wako Pure Chemical In-
dustries, Osaka, Japan) according to the manufacturer’s
instructions. Mutation analysis was performed by poly-
merase chain reaction (PCR) amplifying each of the
seven -Gal A exons and their flanking intronic se-
quences from genomic DNA using one biotinylated
primer in each primer set. A single biotinylated strand
was isolated using streptavidin-coated magnetic beads
and then sequenced by the solid-phase direct method as
previously described [23]. Each mutation was confirmed
by repeat PCR amplification and sequencing of the oppo-
site strand. A mutation was considered disease-causing
whenever there was cosegregation of the lesion and dis-
ease phenotype or low -Gal A activity in each family.
RESULTS
Abnormally low plasma-Gal A activities (2.5 U/mL)
were found in six (1.2%) of the 514 male patients with
renal failure who were not previously diagnosed as hav-
ing Fabry disease. Enzymatic activities in the six patients
ranged from 0.6 to 2.4 U/mL,7% to 28.6% of the mean
activity in 89 healthy males (mean  1 SD, 8.4  2.4
U/mL; range, 4.8 to 17.9 U/mL). The plasma -Gal A
activities in the remaining 508 patients ranged from 4.1
to 29.1 U/mL (mean  1 SD, 9.2  3.7 U/mL) (Fig. 1).
Lymphocyte -Gal A activities in the six patients ranged
from 0.9 to 12.9 U/mg protein,2% to 28% of the mean
activity in 43 healthy male controls (mean 1 SD, 46.4
6.5 U/mg protein; range, 33.4 to 60.9 U/mg protein). The
plasma GL-3 levels were elevated in all six patients,
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Fig. 1. Plasma -galactosidase A (-Gal A) activity in 89 normal
healthy males and 514 males with end-stage renal disease (ESRD) on
hemodialysis. See accompanying text for details.
ranging from 3.6 to 17.7 ng/mL, compared to the normal
mean value of 2.1 ng/mL (range, 1.2 to 2.8 ng/mL SD 
0.7) [22].
The six male patients with low -Gal A activities
ranged in age from 30 to 68 years, were not related by
history, and initiated hemodialysis at 25 to 56 years of
age. Each had been diagnosed with chronic glomerulo-
nephritis. Among the 366 screened patients classified as
having chronic glomerulonephritis, 1.6% actually had
Fabry disease. Of the other screened patients with a
specific diagnosis, no Fabry patients were identified. No-
tably, angiokeratoma and corneal and lenticular opacit-
ies were not observed in any of the six patients. Acropar-
esthesias and hypohidrosis were reported only by patient
6. All but patient 4 had LVH with left ventricular thick-
ness ranging from 14 to 20 mm (Table 1).
Reevaluation of patient 6’s original PAS-stained renal
biopsy specimen revealed subtle foamy inclusions in the
podocytes, consistent with glycosphingolipid deposits
that had been “leeched-out” during fixation. Subsequent
fixation of the original biopsy in osmium to preserve the
glycosphingolipid deposits and staining with toluidine
blue O revealed dark-blue stained granular deposits of
the glycosphingolipid in the epithelial cells and glyco-
sphingolipid inclusions in the capillary endothelial cells
of the glomerulus (Fig. 2A). On electron microscopy,
stacked or concentric lamellar figures, or solid osmophi-
lic-dense material was observed in the epithelial and
endothelial cells, consistent with the glycosphingolipid
deposits characteristic of Fabry disease. Of note, patient
6 had a family history of renal disease. His mother died
from renal failure of unknown cause at 40 years of age
and his older brother died from renal failure at 42 years
of age. Another brother began hemodialysis for renal
insufficiency at 34 years of age; his plasma -Gal A
activity was markedly deficient, consistent with the diag-
nosis of Fabry disease. Like his brother (patient 6), he
has acroparesthesias and hypohidrosis, but did not have
angiokeratoma or corneal clouding. Patient 6’s 34-year-
old sister experienced acroparesthesias during adoles-
cence, but did not have angiokeratoma, hypohidrosis,
or corneal opacities. She had mild albuminuria, normal
serum creatinine (0.4 mg/dL), and normal renal function.
Her plasma -Gal A activity was 6.1 U/mL, consistent
with heterozygosity for Fabry disease. Patient 5 had no
family history of Fabry disease. His father and mother
died at 92 years and at 90 years, respectively. His 34-year-
old daughter had albuminuria, a normal serum creatinine
(1.1 mg/dL), and decreased plasma -Gal A activity (2.4
U/mL). She did not have angiokeratoma, acroparesthe-
sias, hypohidrosis, or corneal/lenticular opacities.
Genomic amplification and solid-phase direct se-
quencing of single-stranded genomic DNA from each of
the six patients identified four different missense muta-
tions. Patients 1, 2, and 3 had G to A transitions of
nucleotide 888 in exon 6, which predicted the substitution
of isoleucine for methionine at residue 296 (M296I). A
three-generation pedigree from each of these patients
failed to reveal evidence of relatedness. Patient 4 had a
G to C transition at nucleotide 196 in exon 2, predicting
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Table 1. Clinical, biochemical, and molecular characteristics of hemodialysis patients with the “renal variant” of Fabry disease
Patients
Characteristic 1 2 3 4 5 6
Age years 30 57 62 68 59 37
Age started hemodialysis years 25 47 56 51 56 35
Original diagnosis CGN CGN CGN CGN CGN CGN
Renal biopsy      
(glomerulosclerosis)
Left ventricular wall thickness mm
Interventricular septum 15 20 17 11 15 17
Posterior wall 12 20 12 11 14 17
Left ventricular fractional shortening 42 28 30 28 40 41
Angiokeratoma      
Acroparesthesias      
Hypohidrosis      
Corneal/lenticular opacities      
-Gal A activity
Plasma U/mL 1.1 1.1 0.9 2.4 0.7 0.6
Lymphocytes U/mg protein 2.7 1.5 3.0 12.9 1.6 0.9
-Gal A mutation
Base substitution G→A G→A G→A G→C C→T G→A
Mutation M291I M291I M291I E66Q A97V G373D
Plasma GL-3 ng/mL 3.7 6.5 3.8 5.6 6.5 17.7
Abbreviations are: -Gal A, -galactosidase A; CGN, chronic glomerulonephritis; GL-3, globotriaosylceramide (normal mean 2.4 ng/mL; range, 1.3–2.8 ng/mL).
-Gal A values in normal males ranged from 4.8 to 17.6 U/mL (mean, 8.42.4; N 	 89) in plasma, and from 33.4 to 60.9 U/mg protein (46.46.5; N 	 43) in
lymphocytes.
Fig. 2. Photomicrograph of a renal biopsy
from patient 6. (A ) Fixation of the original
specimen in osmium and staining with tolu-
idine blue O revealed the glycosphingolipid
deposits in the epithelial cells and in the capil-
lary endothelial cells as observed by light mi-
croscopy (
780). (B ) Electron photomicro-
graph of a uranyl acetate and lead citrate
stained ultrathin section showed stacked or
concentric lamellar inclusions, and/or solid
opaque material in the epithelial and endothe-
lial cells (bar indicates 3 nm).
the substitution of glutamine for glutamic acid at residue
66 (E66Q). The lesion in patient 5 was a C to T transition
at nucleotide 290 in exon 2, which predicted the substitu-
tion of valine for alanine at residue 97 (A97V). Analysis
of genomic DNA from his obligate heterozygous daugh-
ter revealed the A97V mutation, as expected. Patient 6
had a G to A transition of nucleotide 1118 in exon 7,
predicting the substitution of aspartic acid for glycine at
residue 373, a newly identified mutation (G373D). His
affected brother and heterozygous sister also inherited
the G373D mutation.
DISCUSSION
Almost every lysosomal storage disease has severe
early-onset and milder later-onset subtypes with distinct
phenotypes resulting from different mutations in the
same gene (e.g., types A and B Niemann-Pick disease,
infantile and adult Pompe disease, types 1 and 2 Tay-
Sachs disease, and mucopolysaccharidosis types IH and
IS) [24]. Null mutations cause the most severe pheno-
types, while missense, in-frame small deletions, and splic-
ing lesions that encode mutant enzyme proteins with
varying levels of residual activity are responsible for the
milder subtypes. However, it has become increasingly
clear that the phenotypes in each disease are not stereo-
specific, but rather, that different mutations (or combina-
tions of mutations for autosomal-recessive traits) result
in a spectrum of clinical severity for each disease. Such
is the case for Fabry disease, with severe classical and
distinctively milder cardiac variant phenotypes [3]. Among
the over 300 different -Gal A mutations identified to
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date [Human Gene Mutation Database; http://uwcm.ac.
uk/uwcm/mg/hgmd0.html], patients with the classical
phenotype have nonsense, severe missense, frame-shift,
and splicing mutations that result in no enzyme protein
or mutant enzymes with very low activity (1% of nor-
mal mean). In contrast, all cardiac variants described
to date had missense mutations that encoded mutant
enzyme proteins or intronic lesions that markedly re-
duced transcript levels, but resulted in sufficient residual
-Gal A activity (1% to 10% of normal) to modify
the phenotype.
Here, we expand the phenotypic spectrum of Fabry
disease to include patients who develop ESRD at ages
similar to those of classically affected patients, but lack
the other characteristic manifestations of the classic phe-
notype that usually signal its diagnosis, including angio-
keratoma, acroparesthesias, hypohidrosis, and/or cor-
neal and lenticular opacities. Thus, these “renal variants”
have a phenotype that is “intermediate,” between that
of classically affected and cardiac variant patients. Con-
sistent with this concept, the six “renal variants” reported
here had four different missense mutations that ex-
pressed residual -Gal A activity, three of which (E66Q,
A97V, and M296I) were reported previously, in cardiac
variants who did not have renal insufficiency [11, 25, 26].
The fact that the same mutation can occur in different
Fabry subtypes is not novel; for example, classically af-
fected and cardiac variants have been described with the
R112H and G328R lesions [27–29]. The R112H mutation
occurred in a 48-year-old male with the classic pheno-
type, including impaired renal function [29], and in a 56-
year-old male with the cardiac variant phenotype and
mild proteinuria [28]. The G328R mutation was identi-
fied in a 54-year-old male cardiac variant [29] and in a
34-year-old male with the classic disease manifestations,
whose classically affected maternal uncle had developed
renal insufficiency [27]. Thus, certain mutations can re-
sult in different phenotypes, suggesting that modifying
genes and/or environmental factors are involved in de-
termining disease severity. Modifying genes might include
those involved in the synthesis of various -galactosyl-
containing glycolipids, including the blood group glyco-
lipids B, B1, and P1, as the accumulation of these addi-
tional-Gal A substrates may alter disease severity [3, 30].
The diagnosis of Fabry disease is often missed or de-
layed, particularly in the absence of a previously identi-
fied family member [3]. Males with the classic phenotype
typically present in childhood with the characteristic an-
giokeratoma and acroparesthesias. However, if these
signs and symptoms are subtle or absent [31], the disor-
der may not be recognized until adulthood when protein-
uria, renal insufficiency, and/or cardiomyopathy are de-
tected and the diagnosis is belatedly made. In contrast,
“cardiac variants” have no history of acroparesthesias,
do not have angiokeratoma or renal insufficiency, and
may be 50 years of age or older before onset of their
cardiac manifestations. Thus, these mildly affected pa-
tients are easily missed, unless the cardiologist considers
this rare variant in the differential diagnosis of LVH,
dilated cardiomyopathy, hypertrophic obstructive car-
diomyopathy, or idiopathic cardiomegaly [11, 12].
In this report, we further explore the phenotypic spec-
trum of Fabry disease. By determining the plasma -Gal
A activity in a series of 514 male patients undergoing
hemodialysis in Japan, six males (or 1.2%) were found
to have a novel presentation of the disease. All six pa-
tients had been diagnosed as having “chronic glomerulo-
nephritis,” a diagnosis assigned to patients presenting
with uremia and a history of proteinuria for 1 year or
longer. Of note, none of the six patients had angiokera-
toma or the corneal and lenticular dystrophy, which may
have led to their earlier diagnosis. Only patient 6 had
the classic manifestations of acroparesthesias and hypo-
hidrosis. Of note, his affected younger brother also had
acroparesthesias and hypohidrosis, but lacked angioker-
atoma and corneal clouding, indicating that the renal
variant phenotype bred true in this family. Only patient
6 had a renal biopsy. However, the biopsy was routinely
fixed and stained with PAS and examined histologically,
and not by electron microscopy, which provides a more
definitive diagnosis [3, 32]. In retrospect, the histologic
diagnosis could have been made, particularly if the
biopsy had been optimally fixed to preserve the glyco-
sphingolipid deposits for staining with toluidine blue O
(Fig. 2A), or better with methylene blue-azure II [3].
In this series of 514 hemodialysis patients, only 16
(3%) had renal biopsies, similar to other surveys in Japan
where about 5% to 6% of hemodialysis patients with
ESRD have renal biopsies [33]. However, it is a general
policy in Japan not to biopsy patients who present with
ESRD, as was the case for five of the six patients found
to have Fabry disease.
Although the incidence of Fabry disease has not been
determined in Japan, it is clear from this study that Fabry
patients who develop renal insufficiency are missed. Of
note, a recent survey of 440 male dialysis patients in the
Tokyo area revealed two (0.5%) who had unrecognized
Fabry disease, one of which clearly had the classic pheno-
type [34]. In 2000, there were approximately 120,000
male patients in Japan with ESRD on hemodialysis [33].
If even 0.5% of these patients have undiagnosed Fabry
disease, there may be as many as 600 additional patients
with Fabry disease in Japan alone. Analogously, in the
United States in December 2000, the most recent data
available, there were over 125,000 males undergoing he-
modialysis. Of these, 26% were diagnosed with hyper-
tension, 12% with glomerulonephritis, and 20% were
diagnosed with other unknown causes, but most (95%)
had not had kidney biopsies [35, 36]. Therefore, it is
recommended that all patients undergoing renal dialysis
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or transplantation without a specific disease diagnosis
(i.e., diabetes, polycystic kidney disease), particularly
those not having a renal biopsy, be screened for Fabry
disease by a plasma -Gal A assay, which is reliable,
relatively simple, inexpensive and available from com-
mercial and academic laboratories (e.g., http://www.
mssm.edu/genetics/fabry, http://www.kufm.kagoshima-u.
ac.jp/intmed/). This approach was recently implemented
in Italy, and screening of 1765 male renal dialysis patents
identified four (0.23%) who had Fabry disease, with both
the classic and renal variant phenotypes [37]. Thus, the
frequency of unrecognized Fabry disease among male
dialysis patients may vary by racial, ethnic, demographic
group, and nephrologic screening from 0.2% to 1%. Since
less than 10.0% of female carriers for the classic pheno-
type develop renal failure [3, 38–40], screening for cryptic
carriers among female dialysis patients is likely to be
less effective.
CONCLUSION
Fabry disease was identified in 1.2% of male Japanese
patients with ESRD who had been previously diagnosed
as having chronic glomerulonephritis. Most (83%) of
these patients did not have the classic manifestations
that could have facilitated their diagnosis. These findings
suggest that Fabry disease may be underdiagnosed
among renal dialysis and/or transplant patients. In addi-
tion, these studies indicate that the early presenting
symptoms of Fabry disease such as angiokeratoma and
acroparesthesias, may not occur in “renal variants,”
thereby making their clinical diagnosis difficult. How-
ever, these variants can be easily detected by their low
to absent plasma -Gal A activities, and genetic counsel-
ing can be offered to them and their extended families.
Moreover, recognition of these “renal variants” is impor-
tant, since they presumably will develop the late, life-
threatening cardiac and cerebrovascular manifestations
of Fabry disease that may be treated by enzyme replace-
ment therapy [13–16].
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